和铂医药上半年业绩预增47倍:“BD之王”能否持续盈利?

21世纪经济报道
Jul 29, 2025

21世纪经济报道记者季媛媛今年3月,全球制药巨头阿斯利康宣布以1.75亿美元首付款、最高44亿美元里程碑付款,以及37%的溢价入股和铂医药,获得其9.15%的股权。这场被业内称为“中国版再生元-赛诺菲联盟”的交易,揭开了中国创新药企通过技术平台实现爆发式增长的序幕。四个月后,和铂医药发布财报:预期截至2025年6月30日止六个月的盈利介乎约6800万美元(相当于约5.32亿港元)至约7400万美元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10